Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
16.5M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
9.14M
-
Shares change
-
+9.14M
-
Total reported value, excl. options
-
$252M
-
Value change
-
+$252M
-
Number of buys
-
26
-
Price
-
$27.61
Significant Holders of RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT) as of Q4 2019
26 filings reported holding RAPT - RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q4 2019.
RAPT Therapeutics, Inc. - Common Stock, $0.0001 par value per share (RAPT) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.14M shares
of 16.5M outstanding shares and own 55.5% of the company stock.
Largest 10 shareholders include Svennilson Peter (6.78M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.18M shares), Alphabet Inc. (836K shares), VANGUARD GROUP INC (144K shares), BlackRock Inc. (59K shares), NORGES BANK (30K shares), GEODE CAPITAL MANAGEMENT, LLC (29.6K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (16.2K shares), NORTHERN TRUST CORP (14.9K shares), and TD ASSET MANAGEMENT INC (12.9K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.